Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Neoplasm Metastasis 25Leukemia, Myeloid, Acute 25Breast Neoplasms 18Prostatic Neoplasms 16Myelodysplastic Syndromes 15Lymphoma, Large B-Cell, Diffuse 15Leukemia, Lymphocytic, Chronic, B-Cell 15Multiple Myeloma 14Lung Neoplasms 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Colorectal Neoplasms 12Carcinoma, Non-Small-Cell Lung 12Triple Negative Breast Neoplasms 11Pancreatic Neoplasms 11Burkitt Lymphoma 11Neoplasms 9Lymphoma, Mantle-Cell 9Leukemia, Myelomonocytic, Chronic 9Ovarian Neoplasms 8Melanoma 8Stomach Neoplasms 7Lymphoma, T-Cell 7Squamous Cell Carcinoma of Head and Neck 6Lymphoma, B-Cell 6Carcinoma, Renal Cell 6Myeloproliferative Disorders 5Mouth Neoplasms 5Lymphoma 5Leukemia, Biphenotypic, Acute 5Fallopian Tube Neoplasms 5

Interventions

fludarabine phosphate 1Specimen Handling 1Leukapheresis 1Cyclophosphamide 1Blood Component Removal 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Leukemia, Prolymphocytic, B-Cell × Biopsy × Clear all
NCT05418088 2026-05-29

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Ohio State University Comprehensive Cancer Center

Phase 1 Recruiting
54 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡